Compare OOMA & MDXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OOMA | MDXG |
|---|---|---|
| Founded | 2003 | 2006 |
| Country | United States | United States |
| Employees | N/A | 808 |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 517.6M | 625.6M |
| IPO Year | 2015 | 2007 |
| Metric | OOMA | MDXG |
|---|---|---|
| Price | $20.02 | $4.20 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $18.77 | $9.00 |
| AVG Volume (30 Days) | 314.1K | ★ 1.2M |
| Earning Date | 05-27-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 188.46 | 14.29 |
| EPS | ★ 0.09 | N/A |
| Revenue | $114,490,000.00 | ★ $418,630,000.00 |
| Revenue This Year | $20.35 | N/A |
| Revenue Next Year | $4.17 | $13.02 |
| P/E Ratio | $215.11 | ★ N/A |
| Revenue Growth | 9.53 | ★ 19.99 |
| 52 Week Low | $9.79 | $3.03 |
| 52 Week High | $21.96 | $7.99 |
| Indicator | OOMA | MDXG |
|---|---|---|
| Relative Strength Index (RSI) | 55.63 | 56.99 |
| Support Level | $10.78 | $3.50 |
| Resistance Level | $21.57 | $4.45 |
| Average True Range (ATR) | 0.88 | 0.16 |
| MACD | -0.10 | -0.02 |
| Stochastic Oscillator | 52.24 | 40.96 |
Ooma Inc is a communications services company. It is a smart software-as-a-service (SaaS) and unified communications platform that delivers voice and collaboration features, including messaging, intelligent virtual attendants, and video conferencing, and residential phone service provides PureVoice high-definition voice quality, advanced functionality and integration with mobile devices. Its services rely upon the following main elements: multi-tenant cloud service, on-premise devices, desktop and mobile applications, and calling platforms. It generates revenues from the sale of subscriptions and other services.
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, the company sells allografts for ophthalmic surgery and dental applications through licenses to third parties.